Archive for September, 2019

Find a random person on the street and ask them what a cancer drug should do. What are the odds they dont say it should help patients live healthier and longer?

A confluence of forces have pushed clinical trials away from that seemingly central question, with developers and patient groups betting on the promise that aiming at more subtle measures can help bring needed therapies to market faster. But a new study from the British Medical Journal suggests the conventional wisdom may be right and that trend, among others, have led cancer drugs to hit the market based off studies that have a high risk of bias.

Researchers led by London School of Economics Professor Huseyin Naci tracked cancer drug approvals by the European Medical Association over three years from 2014 to 2016. Putting aside 13 trials not based on a randomized control model which have their own set of issues but can be useful for rare diseases and two trials without published data, they evaluated 39 trials that formed the basis of drug approvals in that period according to a standard criteria of bias and found: 19 (49%) were at high risk of bias and the ones that didnt look at improving survival were more likely to be at risk. Only 10 trials primarily looked at improving survival.

Among them, 20% of trials that looked at overall survival had a high risk of bias, compared to 55% of the rest.

Other factors besides endpoint were at play in studies at risk for bias, including missing data and red flags in how data were measured, such as the trial lacking a blinded assessment.

But in their discussion of the results, the authors focused in part on the paucity of trials that looked head-on at whether a drug will help patients survive, warning that trials that look at other surrogate endpoints speed up development but might mislead patients and bring drugs that dont work. Evaluating the study in a BMJ opinion column, Barbara Mintzes and Agnes Vitry took similar aim.

Uncertainty and exaggeration of the evidence that supports approval of cancer drugs causes direct harm if patients risk severe or fatal adverse effects without likely benefit, they wrote. Or forgo more effective and safer treatments.

The push toward these surrogate measures has come from both developers, eager to get their treatments to market, and patient groups hoping to secure access to new remedies as fast as possible. Targeting overall survival on average takes about an extra year, time many cancer patients dont have.

A federal law, the 21st Century Cures Act, that went into effect in 2017 codified that push. Yet data on trials that avoid the central question of elongating and improving quality of life have been mixed.

A 2018 JAMA Internal Medicine review of 52 articles covering 38 trials on a total of 14,000 patients with 12 different cancers from 2000 through 2016 found no significant association between progression-free survival and health-related quality of life.

The study also comes as one of many critically evaluating existing scientific literature in the wake of the replication crisis that broke out most publicly in psychology and has rippled across the sciences. In 2012 Amgens head of research, Glenn Begley,published a paper inNaturerevealing a 10-year company effort to reproduce 53 landmark studies in oncology. They got positive results in 6.

Follow this link:
Cancer trials aimed at 'surrogate' targets miss bigger mark study - Endpoints News

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionallyappear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diegos Paul Mischel published his first study in Sciencein 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors superhuman growth.

That insight and the ensuing five years of research will now get $46 million cash and company infrastructure to ramp into targeted therapies as Boundless Bio emerges from stealth mode with backing from ARCH Venture Partners and City Hill.Questions abound, from what precisely a drug would look like to what even gives rise to these wild DNA, but CEO Zachary Hornby isnt biting his tongue on the potential.

Were thinking about this as a fourth revolution in cancer therapies, Hornby, who was most recently COO of Ignyta, told Endpoints News. The first three revolutions, by Hornbys count, are chemotherapy in the 1940s, the first targeted therapies at the end of the 20th century, and the recent rise of immunotherapy.

The road to such a revolution would be long, but the embattled oncology field may be in need of new direction. A study released in April found 97% of cancer drugs tested in clinical trials failed to make it to market, and this month researchers found systemic targeting problems plagued two decades of cancer research.

The connection between this loose DNA, officially called extrachromosomal DNA or ecDNA, and cancer centers around a baffling and deadly fact about some tumors: While normal cells in a higher-order species like humans dont evolve within a generation, some cancer cells can evolve rapidly, ensuring their survival against attempted treatments. Why? How? Mischels mapping of cancer genome points to ecDNA.

Freed from a cells chromosomes, the DNA can replicate rapidly. That doesnt hurt if they code for nothing or something benign, but if they code for something that gives the cell an advantage, such as EGFR (a growth factor), the cells will grow rapidly as in any classical natural selection model. This, Hornby said, appears in over 25% of cancers, including notoriously hard to treat MET cancers.

EGFR inhibitors already exist to combat cancer cells that have already evolved (or been amplified), but Boundless Bio plans to use Mischels insights to destroy ecDNA in its early stages. Rather than attacking tumors after the cells have already amplified, the company would jam the process that gives rise to the evolution in the first place.

It opens a whole new avenue of cancer targets, including allowing us to pursue patient populations that to this point have been undruggable, Hornby said, pointing to MET and Myc. Thats just a really different approach than your typical targeted therapies.

But how they would do this is still cloudy.

Hornby said the most promising method was jamming the enzymatic machinery the molecular tools and parts that allow DNA to replicate and code proteins as their research has shown the machinery is slightly different in ecDNA than typical DNA. Another method theyre exploring is to inhibit the metabolic pathways ecDNA can use to fulfill the demands caused by its high replication rate; in other words, growing DNA that are hungry and depriving them of food could neutralize them.

Among the most notable things about Boundless potential therapies is that they may be approved for tumor type, rather than cancer type, i.e. like the new drug from Hornbys old company Ignyta, it could treat a wide range of cancers if the patient showed ecDNA was amplifying in the tumor.

The company will also invest in research to discover the underlying mechanism giving rise to ecDNA.

Originally posted here:
'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in debut - Endpoints News

A comprehensive analysis of the Gene Therapy Market including market sizing, market share by competitor, market share by distribution channel, drivers, restraints, product pricing trends, industry quotations, company profiles and market forecasts to 2024 for global market. Gene Therapy market report provides investors, analysts, researchers, business executives and others with analyses and forecasts for the Gene Therapy market, including Gene Therapy production, revenues, competitors marketing strategy and global product selling prices up to 2022.

AccessGlobal Gene Therapy Market Research ReportDetails at: athttps://www.pioneerreports.com/report/197079

About Gene Therapy Industry

The overviews, SWOT analysis and strategies of each vendor in the Gene Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Gene Therapy market are:

Request for Sample Copy of this Gene Therapy Market Report athttps://www.pioneerreports.com/request-sample/197079

Important application areas of Gene Therapy are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Gene Therapy market. The market study on Global Gene Therapy Market 2018 report studies present as well as future aspects of the Gene Therapy Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.

Application of Gene Therapy Market are:

Product Segment Analysis of the Gene Therapy Market is:

Look into Table of Content of Gene Therapy Market Report at https://www.pioneerreports.com/TOC/197079

This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Geographically this report covers all the major manufacturers from India, China, USA, UK, and Japan. The present, past and forecast overview of Gene Therapy market is represented in this report.

Inquire for further detailed information of Gene Therapy Market Report at:https://www.pioneerreports.com/pre-order/197079

Research objectives of Gene Therapy Market:This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Key Benefits of having Gene Therapy Market Report This report will help to develop Business Strategies by understanding the trends shaping and driving Gene Therapy market Organize sales and marketing efforts by identifying the best opportunities for Gene Therapy market To understand the future market competition in the Gene Therapy market.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Report Price: USD 3900

No of Pages in Gene Therapy Market: 145

Analysis & Forecast Time Period: 2015-2024

Purchase Reportathttps://www.pioneerreports.com/checkout/197079

See the article here:
Gene Therapy Market Analysis by Major Companies, Segmentation, Market Dynamics & Trends - Real Viewpoint

Zacks Investment Research upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $1.00 price objective on the stock.

According to Zacks, Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The companys lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States.

TOCA has been the subject of a number of other reports. ValuEngine upgraded Tocagen from a hold rating to a buy rating in a research report on Thursday, August 1st. Leerink Swann set a $5.00 price target on Tocagen and gave the stock a hold rating in a research report on Wednesday, May 22nd. Cantor Fitzgerald downgraded Tocagen from an overweight rating to a neutral rating in a research report on Thursday, September 12th. Robert W. Baird downgraded Tocagen from an outperform rating to a neutral rating in a research report on Thursday, September 12th. Finally, LADENBURG THALM/SH SH downgraded Tocagen from a buy rating to a neutral rating in a research report on Thursday, September 12th. Nine research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $10.26.

Tocagen (NASDAQ:TOCA) last posted its earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, beating analysts consensus estimates of ($0.76) by $0.04. Tocagen had a negative net margin of 300.42% and a negative return on equity of 115.81%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. As a group, sell-side analysts expect that Tocagen will post -2.64 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in TOCA. JPMorgan Chase & Co. raised its holdings in shares of Tocagen by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 476,684 shares of the companys stock valued at $3,074,000 after acquiring an additional 23,293 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Tocagen by 151.0% during the second quarter. Acadian Asset Management LLC now owns 92,450 shares of the companys stock worth $618,000 after acquiring an additional 55,621 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Tocagen by 9.4% during the first quarter. Rhumbline Advisers now owns 25,491 shares of the companys stock worth $277,000 after acquiring an additional 2,188 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Tocagen during the second quarter worth about $551,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Tocagen during the first quarter worth about $1,304,000. Institutional investors and hedge funds own 35.38% of the companys stock.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: Momentum Indicators

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

The rest is here:
Tocagen (NASDAQ:TOCA) Upgraded to Buy by Zacks Investment Research - Mayfield Recorder

***The operating environment for global organizations is increasingly getting complex. This has left organizations playing catch-up with constantly emerging new business strategies. There is a growing demand for the inclusion of best-consulting services in sync with the organizations business strategy. The transformation of functional areas can and should be integrated into every industry. At Coherent Market Insights, we closely interact with our clients to meticulously examine their business consulting needs and accordingly offer tailored solutions through our unmatched business insights and analytics. ***

Coherent Market Insightsnow offers a detailed analysis of theHemophilia Gene Therapy Marketin new research that provides valuable business insights including revenue share, market valuation, and regional spectrum of this vertical. The report is an all-inclusive study of the current market trends, potential drivers and challenges, application landscape, competition situation, and industry-popular growth strategies, which will empower stakeholders to obtain a clear understanding of this domain. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Hemophilia Gene Therapy Market.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/2480

The latest study on Hemophilia Gene Therapy Market is a compilation of in-depth dissection of this business vertical that is projected to attain commendable proceeds during the estimated timeline, recording momentous yearly growth rate through the anticipated duration. The study precisely inspects the Hemophilia Gene Therapy Market and in doing so, it dispenses valuable insights with respect to industry size, revenue approximations, sales capacity, and more. Additionally, the report also examines the segments alongside the driving forces behind the commercialization portfolio of this business.

Overview

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins called clotting factors. There are around 13 types of clotting factors that work with blood platelets, which are necessary for clotting process to initiate. There are three forms of hemophilia A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in clotting factor VIII. Hemophilia B occurs due to deficiency of clotting factor IX and Hemophilia C is caused due to clotting factor XI deficiency. Hemophilia is incurable with current therapeutic options, which only reduces symptoms such as spontaneous bleeding in muscles and joints as well as increased risk for intracranial hemorrhage. These treatment options lasts only for a day and is costly. As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patients body.

One of the key factors that make this report worth a purchase is the extensive outline it presents, pertaining to the competitive landscape of the industry. The study, on the basis of the competitive landscape, segments the market into the companies such asBioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC Sangamo Therapeutics, Inc., and Freeline Therapeutics.. These firms, as is observed, consistently vie with one another in order to accomplish a successful position in the industry.

The key region covered in this report are:

North America:United States, Canada, Mexico

Europe:Germany, France, UK, Russia, Italy, Rest of Europe

Middle East Africa:Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa

Asia-Pacific:China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

A brief outline of the Hemophilia Gene Therapy Market scope:

Additional key understandings mentioned in the report have been listed below:

If you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/2480

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Read more:
Comprehensive Study on Global Hemophilia Gene Therapy Market 20182026 - Coherent Magazine

Axovant Gene Therapies Ltd (NASDAQ:AXGT) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,061,600 shares, a drop of 17.1% from the July 15th total of 1,280,600 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average trading volume of 662,600 shares, the short-interest ratio is presently 1.6 days.

Shares of Axovant Gene Therapies stock traded down $0.23 during trading on Wednesday, hitting $7.63. The companys stock had a trading volume of 78,183 shares, compared to its average volume of 386,879. The stock has a market cap of $178.68 million, a price-to-earnings ratio of -0.95 and a beta of 1.26. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.70 and a quick ratio of 1.70. Axovant Gene Therapies has a 52 week low of $3.81 and a 52 week high of $20.80. The stock has a 50-day moving average price of $6.87 and a two-hundred day moving average price of $4.87.

Axovant Gene Therapies (NASDAQ:AXGT) last released its earnings results on Friday, August 9th. The company reported ($1.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.11. On average, equities analysts predict that Axovant Gene Therapies will post -4.25 EPS for the current fiscal year.

AXGT has been the subject of a number of analyst reports. Cowen reiterated a hold rating on shares of Axovant Gene Therapies in a research report on Tuesday, July 9th. JMP Securities boosted their price objective on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the company an outperform rating in a research report on Thursday, June 6th. Zacks Investment Research downgraded shares of Axovant Gene Therapies from a buy rating to a hold rating in a research report on Wednesday, August 14th. ValuEngine upgraded shares of Axovant Gene Therapies from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, Svb Leerink started coverage on shares of Axovant Gene Therapies in a research report on Friday, June 21st. They set an outperform rating and a $18.00 price objective for the company. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the companys stock. The company presently has an average rating of Buy and an average target price of $26.79.

Several hedge funds and other institutional investors have recently made changes to their positions in AXGT. Primecap Management Co. CA acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $1,400,000. Marshall Wace LLP acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $272,000. Sphera Funds Management LTD. acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $6,794,000. BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies during the second quarter valued at about $1,482,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Axovant Gene Therapies by 955.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the last quarter. Hedge funds and other institutional investors own 13.48% of the companys stock.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: Earnings Reports

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Read this article:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Sees Large Decrease in Short Interest - TechNewsObserver

Global Gene Therapy Market 2019-2025 report is an in-depth study of Gene Therapy industry Size, Share, Trends and Analysis. It gets to the details of the competitive industry structure around the world. The worldwide Gene Therapy market report study, composed of competent standardized instruments such as S.W.O.T Analysis, offers a comprehensive assessment of the worldwide Gene Therapy market.

Gene Therapy business report offers a full percentage estimate of the CAGR of the period in question that will guide consumers to make choices based on the graph.

The study also covers the main players

Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc.

who leads the worldwide Gene Therapy market.

The experts have calculated the size of the global Gene Therapy market on the basis of 2 major aspects: 1) Income and 2) Production Volume. The subtle analysis of the key chunks of the Gene Therapy market and their geographical diversification all the world has also been carried out. Numerous properties of global Gene Therapy market like upcoming aspects and growth factors related to every segment of the report have been put up thoroughly.

by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) Analysis and Industry Forecast till 2025

Sample PDF Download Link: https://www.quintagoinsights.com/global-gene-therapy-market/request-sample/426

The worldwide Gene Therapy market study includes every feature of the worldwide Gene Therapy market right from basic market data to that of multiple significant criteria based on which the worldwide Gene Therapy market was diversified.

Gene Therapy industry research report includes a thorough assessment of present policies, rules, and rules along with the worldwide industry chain. Other than that, the worldwide Gene Therapy market report study also covers variables such as the manufacturing chain, top manufacturers, supply as well as demand for those products along with the price structure as well as income.

Also calculated in the global Gene Therapy market research report is the different properties of supply and demand, the chronological presentation, manufacturing capacity along with the detailed analysis of the global Gene Therapy market.

1. To evaluate the status of worldwide Gene Therapy, future forecasts, opportunities for development, key markets, and important players.

2. To present the growth of Gene Therapy in the U.S., Europe, and China.

3. To profile key players strategically and analyze their development plan and strategies comprehensively.

4. Defining, describing and forecasting the market by type of item, market and main areas.

Inquire about the report here: https://www.quintagoinsights.com/global-gene-therapy-market/enquiry-before-buy/426

In the end, as trading experts across the value chain, our panel of trading experts have made extensive attempts to do this group action and heavy-lifting add order to generate important players with helpful main & secondary information on the world electricity sub metering market for Gene Therapy. Furthermore, the study includes inputs from our trade advisors which can make it easier for important players to save half their time from the internal assessment. Companies Who receive and use this report will benefit fully from the inferences contained in it. With the exception of this, the study also offers an in-depth assessment of Gene Therapy.

Get in Touch with Us :

F- A/104,Sai Atharva Apartment,Near Swaraj Garden,Pimple Saudagar, Pune, IndiaMail: sales@researchandreports.biz

John is the chief editor of News Conduct. He also handles other important responsibilities like advertisements, comment handling, newsletter subscription and much more. John loves art and he is a screenwriter and playwright.

Continued here:
Global Gene Therapy Market Analysis Key Players Opportunities Segmentation and Forecast to 2025 - News Conduct - News Conduct

Axovant Gene Therapies Ltd (NASDAQ:AXGT) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,061,600 shares, a drop of 17.1% from the July 15th total of 1,280,600 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average trading volume of 662,600 shares, the short-interest ratio is presently 1.6 days.

Shares of NASDAQ AXGT traded down $0.23 during trading on Wednesday, hitting $7.63. 78,183 shares of the company traded hands, compared to its average volume of 386,879. The businesss fifty day moving average is $6.87 and its 200 day moving average is $4.87. Axovant Gene Therapies has a fifty-two week low of $3.81 and a fifty-two week high of $20.80. The firm has a market capitalization of $178.68 million, a price-to-earnings ratio of -0.95 and a beta of 1.26. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.70 and a current ratio of 1.70.

Axovant Gene Therapies (NASDAQ:AXGT) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.11. On average, analysts predict that Axovant Gene Therapies will post -4.25 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of AXGT. Sphera Funds Management LTD. acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $6,794,000. Primecap Management Co. CA acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $1,400,000. BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies in the 2nd quarter worth about $1,482,000. Marshall Wace LLP acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $272,000. Finally, Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% in the 2nd quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the last quarter. Institutional investors own 13.48% of the companys stock.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: Earnings Reports

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Here is the original post:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Short Interest Update - Tech Know Bits

Regenxbio (NASDAQ:RGNX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

A number of other brokerages have also issued reports on RGNX. Svb Leerink upgraded shares of Regenxbio from an underperform rating to a market perform rating and decreased their target price for the stock from $38.00 to $37.00 in a research report on Tuesday, August 20th. ValuEngine upgraded shares of Regenxbio from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Leerink Swann upgraded shares of Regenxbio from an underperform rating to a market perform rating in a research report on Tuesday, August 20th. They noted that the move was a valuation call. BidaskClub upgraded shares of Regenxbio from a strong sell rating to a sell rating in a research report on Thursday, September 12th. Finally, Raymond James initiated coverage on shares of Regenxbio in a research report on Thursday, June 13th. They set an outperform rating on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Regenxbio currently has a consensus rating of Hold and a consensus target price of $79.56.

Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks consensus estimate of ($0.50) by $0.46. Regenxbio had a negative net margin of 88.57% and a negative return on equity of 15.39%. The firm had revenue of $7.88 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter last year, the business earned $0.30 earnings per share. Regenxbios revenue was down 80.3% compared to the same quarter last year. As a group, equities analysts predict that Regenxbio will post -2.85 EPS for the current year.

In other Regenxbio news, insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction on Friday, July 19th. The shares were sold at an average price of $49.49, for a total value of $742,350.00. Following the transaction, the insider now owns 261,000 shares in the company, valued at approximately $12,916,890. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Patrick J. Christmas sold 5,486 shares of the firms stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $42.00, for a total transaction of $230,412.00. Following the completion of the transaction, the senior vice president now directly owns 8,058 shares in the company, valued at approximately $338,436. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,486 shares of company stock worth $1,786,162. 13.80% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Regenxbio by 3.5% in the 2nd quarter. BlackRock Inc. now owns 5,047,103 shares of the biotechnology companys stock valued at $259,270,000 after acquiring an additional 169,888 shares during the period. Royal Bank of Canada raised its stake in shares of Regenxbio by 36.2% in the 2nd quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology companys stock valued at $201,000 after acquiring an additional 1,040 shares during the period. UBS Group AG raised its stake in shares of Regenxbio by 438.6% in the 2nd quarter. UBS Group AG now owns 263,094 shares of the biotechnology companys stock valued at $13,515,000 after acquiring an additional 214,244 shares during the period. Nuveen Asset Management LLC purchased a new position in shares of Regenxbio in the 2nd quarter valued at $10,206,000. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Regenxbio by 0.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 119,714 shares of the biotechnology companys stock valued at $6,150,000 after acquiring an additional 752 shares during the period. 79.40% of the stock is currently owned by institutional investors and hedge funds.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: What is the accumulation/distribution indicator?

Get a free copy of the Zacks research report on Regenxbio (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Read this article:
Regenxbio (NASDAQ:RGNX) Downgraded by Zacks Investment Research to Sell - Mayfield Recorder

The report titled,Global Gene Therapy Market Professional Insight Survey and Forecast to 2028is recently generated by MarketResearch.biz. This research study includes the investigations done of the past progress, present ongoing market scenarios, and future prospects. The report analysis of Gene Therapy incorporates market size & share, upstream circumstance, in detail segmentation outlook, price & cost, and industry environment. It starts from the overview of industry chain structure and depicts the upstream. Besides, the report examinations market size and estimate in different geographies, type, and end-use segment, in addition, the report presents market competition overview among the major organizations and companies profiles, besides, market price and channel highlights are covered in the report.

This statistical surveying research report deals with the present scenario of the market. This investigation report summarizes the technologies, which can help to scale up the growth of the businesses in the near future and obtainable in a clear and professional manner with effective infographics. It clarifies a thorough synopsis of Gene Therapy market dependent on the central parameters. merchandises, End users, provinces and many other subdivisions are planned and elucidated. A transitory idea about the dynamic forces which help make the market more prosperous is deliberated in order to help customer appreciate the future market situation.

Prominent Top Key Vendors of Gene Therapy Report:-Novartis, Kite Pharma Inc, GlaxoSmithKline PLC, Spark Therapeutics Inc, Bluebird bio Inc, Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica PLC, NewLink Genetics Corp., Amgen Inc

Looking for more information on this Research Study? Click Here @https://marketresearch.biz/report/gene-therapy-market/request-sample

Objectives of theGene TherapyStudy:

Identification and measurement of global and enzymatic and reactive universal enzymes based on end-user, product, key application, and geometric region.

To identify the key micro-energy markets and their drivers in the Global Micro Enzymes market and their buyers and reagents, which are expected to provide growth opportunities in the coming years.

Identify market participants and opportunities for market participants and access payment details for major market leaders.

For detailed information about the key factors affecting market growth (drivers, restraints, issues, and opportunities).

For the four main areas, notably, North America (United States, Canada)), Europe (Germany, Spain, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, India, Australia, and South Korea), and the rest (of Latin America and the Middle East & Africa).

To analyze the market structure and the key players involved in the Global Enzymes market and their buyers and reagents in the market and to evaluate in detail their key competencies.

To track and analyze the competitive landscape such as market sharing research and competitive leadership.

For the successful business viewpoint, the market study also examines different worldwide areas, for example, North America, Latin America, Asia-Pacific, Europe, The Middle East, and Africa by considering various segments for example vector type, gene type, application, and region. SWOT and Porters five analysis are also successfully discussed to analyze informative data such as cost, prices, revenue, and end-users. Gene Therapy research report has been evaluated base on various attributes such as manufacturing base, products or services and raw material to comprehend the necessities of the organizations. Apart from the regional outlook, the report also draws attention to leading industry key players to know the successful sales strategies of the businesses. Gene Therapy report can effectively help companies and decision-makers in addressing these challenges strategically to gain the maximum benefits in the highly competitive Gene Therapy Market.

Gene Therapy Market Segmentation byvector type, gene type, application, and region:-

By Vector:Viral vectorRetrovirusesLentivirusesAdenovirusesAdeno Associated VirusHerpes Simplex VirusPoxvirusVaccinia VirusNon-viral vectorNaked/Plasmid VectorsGene GunElectroporationLipofection

By Gene Therapy:AntigenCytokineTumor SuppressorSuicideDeficiencyGrowth factorsReceptorsOther

By Application:Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

Fill Free with your Queries to Get a Call From Our Industry Expert @https://marketresearch.biz/report/gene-therapy-market/#inquiry

Gene Therapy MarketTable Of Content Overview:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Introduction to Market Drivers & Restraints

4.3 Market Drivers

4.3.1 Rising Adoption of Mega Data Centers

4.3.2 Rising Adoption of Cloud Computing

4.4 Market Restraints

4.4.1 High Initial Investment

4.5 Industry Attractiveness Porters Five Force Analysis

4.5.1 Threat of New Entrants

4.5.2 Bargaining Power of Buyers/Consumers

4.5.3 Bargaining Power of Suppliers

4.5.4 Threat of Substitute Products

4.5.5 Intensity of Competitive Rivalry

5 TECHNOLOGY SNAPSHOT

6 MARKET SEGMENTATION

6.1 By Type

6.1.1 Solutions

6.1.1.1 Power Distribution Unit

6.1.1.2 UPS

6.1.1.3 Busway

6.1.1.4 Other Solutions

6.1.2 Services

6.1.2.1 Consulting

6.1.2.2 System Integration

6.1.2.3 Professional Service

6.2 By End-user Application

6.2.1 Information Technology

6.2.2 Manufacturing

6.2.3 BFSI

6.2.4 Government

6.2.5 Energy

6.2.6 Other End-user Applications

6.3 Geography

6.3.1 North America

6.3.2 Europe

6.3.3 Asia-Pacific

6.3.4 Latin America

6.3.5 the Middle East & Africa

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles

8 INVESTMENT ANALYSIS

9 MARKET OPPORTUNITIES AND FUTURE TRENDS

For Information of Multiple Category related Research Report, Visit @https://marketresearch.biz/categories/

About us:

Marketresearch.biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge.

Get in touch with us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Email:inquiry@marketresearch.biz

Originally posted here:
New Edition 2019-2028: Global Gene Therapy Market Insight Inflation & Massive Growth - Market News Live

Cat owners and enthusiasts have heard a number of fascinating myths about male calico cats. While they are relatively rare, with an estimated one male in 3,000 calico cat births, there is no extraordinary demand for them. They do not make good breeding studs because almost all male calicos are sterile. In fact, only about one in 10,000 male calicos is fertile.

Some people have the misconception that calico kittens and cats comprise a specific cat breed. However, calico is the description of a cat's coloration. Cats of many breeds can be a calico, or true tricolor, as a result of their genetic heritage.

Unlike cats with tortoiseshell coloring, the coats of calico cats are of three distinct colors - red, black and white, or a variation of those colors.

Male calicos are a genetic anomaly. Cats, like humans, have two sex chromosomes. Chromosomes carry genes and determine an animal's traits. The required red color for a calico cat is passed only on a female (X) chromosome. How then can a male cat inherit the red colored required for a calico cat?

To put it simply, two chromosomes determine gender. Each parent contributes one chromosome to the offspring. The mother, who has only X chromosomes, always contributes an X chromosome. The father who has both X and Y chromosomes, can contribute either an X or a Y chromosome to his offspring. Thus, it is the father who determines the sexes of his kittens. The red color gene cannot be passed to a male offspring due to unusual characteristics of the gene in question. Under certain conditions, when the red genes are passed to a female offspring, she displays not the expected red or orange coat, but the tricolor coat of a true calico cat.

How then can a male be a true calico? Sometimes there is an incomplete division of the chromosome pair when the chromosomes are separating at the time of fertilization. When that happens, the incomplete chromosome ends up attached to another of the two required chromosomes, giving the offspring one of the following combinations:

In both cases, the result is a male cat who can inherit the trait for a true calico coat. Among humans, this genetic arrangement is called Klinefelter syndrome. A male calico usually cannot sire offspring because the genetics described above almost always guarantees that he will be sterile.

One might suppose that male calicos would bring a high price among breeders because of their rarity. You may even see some websites claiming a purebred male calico cat can fetch a price as high as $1,000 to $2,000. The truth is, while they are an interesting phenomenon, they are of little interest to breeders because they are sterile. It's possible a pet owner might want to pay that amount of money to own a cat that's a rarity, but chances are if you're looking to buy a male calico cat don't expect to pay much more than you would for any regular unpedigreed house cat.

Although most male calicos are sterile, it is a good idea to neuter them to deter spraying and other unwelcome male behaviors. Despite their limitations, they are still boys at heart!

As mentioned earlier, male calico cats have distinctive tricolor coats, but they are not a separate breed. In fact, as many as 16 different cat breeds can have calico coloration, and male calicos can occur among any of those breeds. Some common breeds that may have calico coloration are:

Male calico cats are the offspring with a genetic anomaly of parents representing many possible cat breeds. While female calico cats are quite common, true male calicos are rare and of particular interest for the combination of their unique coloration and sex. While it's a myth that they can command a high price among cat fanciers, if you happen to own a male calico, you can treasure him for his rare condition and other wonderful feline attributes!

Excerpt from:
Myths and Facts About Male Calico Cats | LoveToKnow

Science and technology are often considered to be the forte of men. Nevertheless, the contribution of women to the progress of these areas cannot be disregarded. There have been numerous gifted and far-famed women scientists in history who made crucial discoveries and inventions in the world of science.

Today on our Science Blog, well take a look at some of the most famous women scientists and their achievements.

Polish-born French physicist and chemist best known for her contributions to radioactivity.

British primatologist and ethologist, widely considered to be the worlds foremost expert on chimpanzees.

Advertisements

German-born American physicist who received Nobel Prize for suggesting the nuclear shell model of the atomic nucleus.

American marine biologist and conservationist whose work revolutionzied the global environmental movement.

British biophysicist best known for her work on the molecular structures of coal and graphite, and X-ray diffraction.

American scientist and cytogeneticist who received Nobel Prize in 1983 for the discovery of genetic transposition.

Italian neurologist who received Nobel Prize in 1986 for the discovery of Nerve growth factor (NGF).

American biochemist and pharmacologist who received the 1988 Nobel Prize in Physiology or Medicine.

American physician who was the first woman to become a medical doctor in the United States.

German biologist who received the Albert Lasker Award for Basic Medical Research in 1991.

Advertisements

More:
10 Famous Women Scientists in History